|
Report Date : |
16.07.2012 |
IDENTIFICATION DETAILS
|
Name : |
LEAWELL INTERNATIONAL LTD. |
|
|
|
|
Registered Office : |
18/F., Catic Plaza, |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
22.10.1991 |
|
|
|
|
Com. Reg. No.: |
15143500 |
|
|
|
|
Legal Form : |
Private Limited Company. |
|
|
|
|
Line of Business : |
Importer, Re-exporter and Wholesaler of Chemicals, chemical raw materials, pharmaceuticals, etc. |
|
|
|
|
No. of Employees : |
10. (Including affiliates) |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Good |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
Hong Kong |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
LEAWELL INTERNATIONAL
LTD.
ADDRESS: 18/F., Catic Plaza, 8
Causeway Road, Causeway Bay, Hong Kong.
PHONE: 2576 0298
FAX: 2895 4635; 2577 4618
E-MAIL: enquiry@leawell.com.hk
Managing Director: Mr. Wang Wei
Incorporated on: 22nd
October, 1991.
Organization: Private
Limited Company.
Capital: Nominal: HK$100,000.00
Issued: HK$100,000.00
Business Category: Importer, Re-exporter and Wholesaler.
Employees:
10. (Including affiliates)
Main Dealing Banker: Bank of China (Hong Kong) Ltd., Hong Kong.
Banking Relation: Satisfactory.
Registered Head Office:-
18/F., Catic Plaza, 8 Causeway Road, Causeway Bay, Hong Kong.
China Offices:-
Shanghai Office
Room
1106, Oasis Tower & Hotel, 555 West Zhong Shan Road, Shanghai, China.
Post code: 200051
Tel: 86-021-6286 3898
Fax: 86-021-6286 2618
E-mail: dragon3958@163.com
Xi’an Office
Room
703, Building A5, Yazhuo Garden, 153 North Hancheng Road, Xi’an, China.
Post code: 710077
Tel: 86-029-8861 6862
Fax: 86-029-8861 6860
E-mail: zhaojie67@263.net
Sister/Affiliated Companies:-
Beijing Century Leawell Medicine Development Ltd., China
Guangdong Leawell Pharmaceutical Co. Ltd., China.
Leawell (China) Ltd., Hong Kong.
(Same address)
Leawell Pharmaceutical Ltd., Hong Kong.
(Same address)
Shantou Jinshi Antibiotics Pharmaceutical Ltd., China.
15143500
0330367
Managing Director: Mr. Wang Wei
Director & Sales Contact: Ms.
Chen Dan, Danna
Nominal Share Capital: HK$100,000.00 (Divided into 100,000 shares of
HK$1.00 each)
Issued Share Capital: HK$100,000.00
(As per registry dated 22-10-2011)
|
Name |
|
No. of shares |
|
WANG Wei |
|
50,000 |
|
CHEN Dan |
|
50,000 |
|
|
|
––––––– |
|
|
Total: |
100,000 ====== |
(As per registry dated 22-10-2011)
|
Name (Nationality) |
Address |
|
CHEN Dan |
Flat C, 9/F., Tower 1, The Floridian, 18 Sai Wan Terrace, Quarry Bay,
Hong Kong. |
|
WANG Wei |
Flat C, 9/F., Tower 1, The Floridian, 18 Sai Wan Terrace, Quarry Bay,
Hong Kong. |
(As per registry dated 22-10-2011)
|
Name |
Address |
Co. No. |
|
Chartac Secretaries Ltd. |
7/F., Allied Kajima Building, 138 Gloucester Road, Wanchai, Hong Kong. |
0216220 |
The subject was incorporated on 22nd October, 1991 as a private limited
liability company under the Hong Kong Companies Ordinance.
Apart from these, neither material change nor amendment has been ever
traced and noted.
Activities: Importer,
Re-exporter and Wholesaler.
Lines: Chemicals,
chemical raw materials, pharmaceuticals, etc.
Employees: 10. (Including affiliates)
Commodities Imported: Imported from Europe, India and Southeast Asia.
Markets: Hong
Kong, China, other Asian countries, Europe, etc.
Terms/Sales:
L/C or as per
contracted.
Terms/Buying: L/C,
T/T or D/P, etc.
Nominal Share Capital: HK$100,000.00 (Divided into 100,000 shares of
HK$1.00 each)
Issued Share Capital: HK$100,000.00
Mortgage or Charge:-
Date of General
Letter of Hypothecation (Serial No. 20934):
06-07-1994
Amount: To
secure the repayment to the Bank of all moneys now or hereafter and from time
to time owing, whether immediately payable or otherwise, by the Company to the
Bank or for which the Company may be liable to the Bank on any account
whatsoever either solely or jointly and severally with other person or persons
Property: All
property, goods, merchandise, shares, stocks, documents of title and securities
for property or money now or hereafter and from time to time lodged or
deposited with or in the name of the Bank on the Company’s account, or coming
into the possession or control of the Bank on the Company’s account, or held by
the Company or by others on the Company’s account under lien to the Bank
Mortgagee: The
Kwangtung Provincial Bank, Hong Kong Branch. [Merged into Bank of China (Hong Kong)
Ltd.]
Profit & Loss: Making a small profit.
Condition:
Keeping in a
satisfactory state.
Facilities:
Making rather
active use of general banking facilities.
Payment:
Met trade
commitments as required.
Commercial Morality: Satisfactory.
Bankers:-
Bank of China (Hong Kong) Ltd.,
Hong Kong.
The Bank of Tokyo-Mitsubishi UFJ Ltd.,
Hong Kong Branch.
The Hongkong & Shanghai Banking Corp.
Ltd., Hong Kong.
Standing: Good.
Leawell International Ltd. is a private limited company equally owned
and set up by Mr. Wang Wei and Ms. Danna Chen Dan. They are also directors of the subject.
Based in Hong Kong, the subject is engaged in marketing and distributing
pharmaceuticals and chemical raw materials, intermediates, pharmaceutical
finished dosages and medical equipment.
The subject is a bridge between China and overseas pharmaceutical and
chemical field. It is an agent in China
for the marketing and selling the products from many pharmaceutical
manufacturers from Italy, Germany, Spain, Austria, the Netherlands, France,
Mexico, the Republic of Slovak, South Korea, India, Taiwan, etc. In addition, the subject also helps overseas
manufacturers apply for over 30 Import Drug License [IDL].
According to the subject, it submits an average of 10 import
pharmaceutical applications every year.
Besides, the subject also exports Chinese pharmaceutical raw materials
and intermediates to the European countries, acting as an agent for Chinese
manufacturers to apply “DMF” and “COS” registration.
The subject has won the recognition in local antibiotics importing and
exporting fields.
The subject has established a joint venture Shantou Jinshi Antibiotics
Pharmaceutical Ltd. in Shantou, Guangdong Province, China in 2002. This firm is producing antibiotics API such
as Cephalosporis and Penicillins, and finished dosages.
The subject is not only cooperating with Harbin Pharm Group Sanchine
Pharmaceutical Shareholding Co. Ltd., a China-based pharmaceutical Group, to
develop new finished formula, but also acting as the marketing agent and
registration agent of the Royal Jelly products of Beijing Zizhu Pharmaceutical
Co. Ltd. in Hong Kong. It also helps the
Chinese pharmaceutical companies register their Chinese medicine products in
Hong Kong.
Since establishment, the subject has established an extensive and
long-term cooperation relationship with the pharmaceutical companies and
manufacturers in China. It is
experienced in the mass production of a variety of sterile product dosage
forms, including sterile injection powder, injection, tablets, capsules,
suppository, ointments, eye-drop, etc.
It is also experienced in processing the pharmaceutical and chemical raw
materials and intermediates in China.
Its subsidiary, Guangdong Leawell Pharmaceutical Co. Ltd., owns
operation licenses for all types of API, finished dosages and medical
equipments with GSP certificate. While
its subsidiary in Beijing, Beijing Century Leawell Pharmaceutical Development
Ltd, is responsible for the IDL, COS and DMF applications and technical
consultation. The subject also has a
subsidiary in Shanghai, which is responsible for the export. Over the past 15 years, the subject has
established an extensive and long-term cooperation relationship with hundreds
of reputable pharmaceutical companies and manufacturers in China and all over
the world.
The subject exports the following pharmaceuticals: Nitrendipine,
Metoclpramide, Fenofibrate, Piroxicam, Fenbufen, TAA, TAEM, Sulbactam Sodium,
Streptomycin Sulfate Sterile, TTZ, Fosfomycin Sodium, Amikacin Base,
Glimepiride, trazodone cloridrato 50mg tablet, Ipratropium, Glimepiride,
Telmisartan, Pramiracetam Sulfate, Minocycline HCl, etc.
In Hong Kong, the subject has got affiliated companies Leawell (China)
Ltd. and Leawell Pharmaceutical Ltd. located at the same address. The latter firm is engaged in the same lines
of business as the subject, more or less.
However, it is cooperating with European firms.
The overall business of the subject is active.
In 1997, two lawsuits were recorded against the subject which was sued
by several foreign pharmaceuticals suppliers in Hong Kong.
Mr. Wang Wei and Ms. Chen Dan were China merchants but have been in Hong
Kong for a long time. They have already
become Hong Kong ID Card holders.
The subject’s history in Hong Kong is over twenty-years.
On the whole, consider it good for normal business engagements.
Court case:-
|
Date |
Plaintiff |
Defendant |
Cause |
Amount |
|
May 1997 |
Astra Aktiebolag, Aktiebolaget Hassle, Astra Pharmaceuticals (HK) Ltd.
and Astra Pharmaceutical Production Aktiebolag |
Leawell International Ltd. and Chen Dan |
Declaration |
Not stated |
|
June 1997 |
Roussel Uclaf S.A. |
Leawell International Ltd. |
Injunction |
Not stated |
Property information of
director:-
Property Location: Flat C on 9/F. of Tower 1, The
Floridian, 18 Sai Wan Terrace, Hong Kong.
Owner: Wang Wei
Date of Purchase: 15-09-1997
Purchased Price: HK$12,264,000
Incumbrances:-
|
Date of Mortgage |
Amount Consideration |
Mortgagee |
Nature |
|
15-09-1997 |
- |
The Kwangtung Provincial Bank, Hong Kong Branch. [Merged into Bank of China (Hong Kong)
Ltd.] |
Charge to secure general banking facilities |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.55.65 |
|
|
1 |
Rs.85.89 |
|
Euro |
1 |
Rs.67.88 |
INFORMATION DETAILS
|
Report Prepared
by : |
PRL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.